Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ABBV-706 versus standard of care in relapsed/refractory small cell lung cancer
2025-523819-11-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of turmetabart adizutecan and topotecan in small cell lung cancer (SCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Objective response rate and Overall survival. Planned start Aug 2026; status: authorised.
02
Drugs
turmetabart adizutecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-523819-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523819-11-00.